Literature DB >> 8348931

Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods.

M E Ramsay1, C P Farrington, E Miller.   

Abstract

A national survey was conducted of 3150 notified cases of whooping cough in order to determine age-specific pertussis vaccine efficacy by the 'screening' method. The cases were collected over two periods, one just prior to the start and one at the first peak of the whooping cough epidemic of 1989-90. Vaccination status was determined by a postal questionnaire to the reporting doctor and clinical data were also collected to provide efficacy estimates according to standardized case definitions. Overall, observed vaccine efficacy was high but differed between epidemic (87%) and non-epidemic (93%) periods (P = 0.03). Efficacy estimates were generally higher for typical or severe cases than for children with an atypical illness. Vaccine efficacy declined with age (P < 0.01) but estimates remained high up to the age of 8 years. This study will provide baseline data for comparison with efficacy observed from similar studies of children immunized at an accelerated schedule and from phase III studies of acellular pertussis vaccines performed elsewhere.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348931      PMCID: PMC2271201          DOI: 10.1017/s095026880005665x

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  15 in total

1.  The measurement and interpretation of age-specific vaccine efficacy.

Authors:  C P Farrington
Journal:  Int J Epidemiol       Date:  1992-10       Impact factor: 7.196

Review 2.  Assessing vaccine efficacy in the field. Further observations.

Authors:  W A Orenstein; R H Bernier; A R Hinman
Journal:  Epidemiol Rev       Date:  1988       Impact factor: 6.222

3.  A search for subclinical infection during a small outbreak of whooping cough: implications for clinical diagnosis.

Authors:  D Jenkinson; J D Pepper
Journal:  J R Coll Gen Pract       Date:  1986-12

4.  Field evaluation of vaccine efficacy.

Authors:  W A Orenstein; R H Bernier; T J Dondero; A R Hinman; J S Marks; K J Bart; B Sirotkin
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

5.  Whooping-cough notifications.

Authors:  E Miller; B Jacombs; T M Pollock
Journal:  Lancet       Date:  1980-03-29       Impact factor: 79.321

Review 6.  Reflections on the efficacy of pertussis vaccines.

Authors:  P E Fine; J A Clarkson
Journal:  Rev Infect Dis       Date:  1987 Sep-Oct

7.  Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study.

Authors:  D Jenkinson
Journal:  Br Med J (Clin Res Ed)       Date:  1988-02-27

8.  Severity of notified whooping cough.

Authors:  C L Miller; W B Fletcher
Journal:  Br Med J       Date:  1976-01-17

9.  Severity of whooping cough in England before and after the decline in pertussis immunisation.

Authors:  T M Pollock; E Miller; J Lobb
Journal:  Arch Dis Child       Date:  1984-02       Impact factor: 3.791

10.  Effect of vaccination on severity and dissemination of whooping cough.

Authors:  P R Grob; M J Crowder; J F Robbins
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-13
View more
  13 in total

Review 1.  Immune persistence after pertussis vaccination.

Authors:  Zhiyun Chen; Qiushui He
Journal:  Hum Vaccin Immunother       Date:  2017-01-03       Impact factor: 3.452

2.  Vaccination strategies against respiratory syncytial virus.

Authors:  Dan Yamin; Forrest K Jones; John P DeVincenzo; Shai Gertler; Oren Kobiler; Jeffrey P Townsend; Alison P Galvani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

3.  Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine.

Authors:  Jennie S Lavine; Ottar N Bjørnstad; Birgitte Freiesleben de Blasio; Jann Storsaeter
Journal:  Vaccine       Date:  2011-11-26       Impact factor: 3.641

Review 4.  Which strategy for pertussis vaccination today?

Authors:  Dorota Z Girard
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data.

Authors:  H E de Melker; J F Schellekens; S E Neppelenbroek; F R Mooi; H C Rümke; M A Conyn-van Spaendonck
Journal:  Emerg Infect Dis       Date:  2000 Jul-Aug       Impact factor: 6.883

6.  Whole-cell pertussis vaccine induces low antibody levels in human immunodeficiency virus-infected children living in sub-Saharan Africa.

Authors:  Mathurin C Tejiokem; Elisabeth Njamkepo; Ionela Gouandjika; Dominique Rousset; Lydie Béniguel; Catherine Bilong; Gilbert Tene; Ida Penda; Carine Ngongueu; Jean C Gody; Nicole Guiso; Laurence Baril
Journal:  Clin Vaccine Immunol       Date:  2009-02-04

7.  Modelling the impact of extended vaccination strategies on the epidemiology of pertussis.

Authors:  M H Rozenbaum; R De Vries; H H LE; M J Postma
Journal:  Epidemiol Infect       Date:  2011-11-24       Impact factor: 2.451

8.  Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia.

Authors:  Patricia Campbell; Peter McIntyre; Helen Quinn; Linda Hueston; Gwendolyn L Gilbert; Jodie McVernon
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

9.  Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model.

Authors:  Robin de Vries; Mirjam Kretzschmar; Joop F P Schellekens; Florens G A Versteegh; Tjalke A Westra; John J Roord; Maarten J Postma
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

10.  Accelerating control of pertussis in England and Wales.

Authors:  Helen Campbell; Gayatri Amirthalingam; Nick Andrews; Norman K Fry; Robert C George; Timothy G Harrison; Elizabeth Miller
Journal:  Emerg Infect Dis       Date:  2012-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.